Genotype-Driven Treatment of Advanced Non-Small Cell Lung Cancer Based on mRNA Expression of ERCC1 and RRM1 as First-Line Chemotherapy.

Trial Profile

Genotype-Driven Treatment of Advanced Non-Small Cell Lung Cancer Based on mRNA Expression of ERCC1 and RRM1 as First-Line Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Carboplatin; Gemcitabine; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 04 Mar 2014 According to ClinicalTrials.gov record planned end date changed from 1 Jul 2015 to 1 Feb 2015.
    • 04 Mar 2014 According to ClinicalTrials.gov record planned end date changed from 1 Jul 2015 to 1 Feb 2015.
    • 26 Jul 2012 Planned number of patients changed from 117 to 162 as reported by ClinicalTrials.gov (NCT01648517).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top